Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9

Benzinga · 12/22/2025 12:19
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $9.